| Autor: |
O V Pyankov, A A Isaeva, Mariya B Borgoyakova, A. P. Rudometov, N V Danilchenko, Larisa I. Karpenko, E A Volosnikova, S V Belenkaya, L. A. Orlova, D N Shcherbakov, N V Volkova, D. E. Murashkin, D. V. Shanshin, V S Nesmeyanova, A V Zaikovskaya, Alexander A. Ilyichev, Ekaterina V Starostina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Молекулярная биология. 55:987-998 |
| ISSN: |
0026-8984 |
| Popis: |
The development of preventive vaccines became the first order task in the COVID-19 pandemic caused by SARS-CoV-2. This paper reports the construction of the pVAX-RBD plasmid containing the Receptor-Binding Domain (RBD) of the S protein and a unique signal sequence 176 which promotes target protein secretion into the extracellular space thereby increasing the efficiency of humoral immune response activation. A polyglucine-spermidine conjugate (PGS) was used to deliver pVAX-RBD into the cells. The comparative immunogenicity study of the naked pVAX-RBD and pVAX-RBD enclosed in the PGS envelope showed that the latter was more efficient in inducing an immune response in the immunized mice. In particular, RBD-specific antibody titers were shown in ELISA to be no higher than 1 : 1000 in the animals from the pVAX-RBD group and 1 : 42000, in the pVAX-RBD-PGS group. The pVAX-RBD-PGS construct effectively induced cellular immune response. Using ELISpot, it has been demonstrated that splenocytes obtained from the immunized animals effectively produced INF-y in response to stimulation with the S protein-derived peptide pool. The results suggest that the polyglucine-spermidine conjugate-enveloped pVAX-RBD construct may be considered as a promising DNA vaccine against COVID-19. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
